These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30206710)

  • 1. Genetic variations using whole-exome sequencing might predict response for neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Lee IH; Kang K; Kang BW; Lee SJ; Bae WK; Hwang JE; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    Med Oncol; 2018 Sep; 35(11):145. PubMed ID: 30206710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Genotype Signature for Predicting Pathologic Complete Response in Locally Advanced Rectal Cancer.
    Xiao WW; Li M; Guo ZW; Zhang R; Xi SY; Zhang XG; Li Y; Wu DQ; Ren YF; Pang XL; Wan XB; Li K; Zhou CL; Zhai XM; Liang ZK; Wang QX; Zeng ZF; Zhang HZ; Yang XX; Wu YS; Li M; Gao YH
    Int J Radiat Oncol Biol Phys; 2021 Jun; 110(2):482-491. PubMed ID: 33434612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy.
    Machackova T; Trachtova K; Prochazka V; Grolich T; Farkasova M; Fiala L; Sefr R; Kiss I; Skrovina M; Dosoudil M; Berindan-Neagoe I; Svoboda M; Slaby O; Kala Z
    Cancer Genomics Proteomics; 2020; 17(3):249-257. PubMed ID: 32345666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating serum microRNA-345 correlates with unfavorable pathological response to preoperative chemoradiotherapy in locally advanced rectal cancer.
    Yu J; Li N; Wang X; Ren H; Wang W; Wang S; Song Y; Liu Y; Li Y; Zhou X; Luo A; Liu Z; Jin J
    Oncotarget; 2016 Sep; 7(39):64233-64243. PubMed ID: 27572313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dynamic nomogram for predicting pathologic complete response to neoadjuvant chemotherapy in locally advanced rectal cancer.
    Wang G; Li J; Huang Y; Guo Y
    Cancer Med; 2024 Jun; 13(11):e7251. PubMed ID: 38819440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer using 18FDG-PET/CT.
    Shanmugan S; Arrangoiz R; Nitzkorski JR; Yu JQ; Li T; Cooper H; Konski A; Farma JM; Sigurdson ER
    Ann Surg Oncol; 2012 Jul; 19(7):2178-85. PubMed ID: 22395978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel biomarkers to predict treatment response and prognosis in locally advanced rectal cancer undergoing neoadjuvant chemoradiotherapy.
    Guan B; Xu M; Zheng R; Guan G; Xu B
    BMC Cancer; 2023 Nov; 23(1):1099. PubMed ID: 37953237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of pathological complete response rates after neoadjuvant short-course radiotherapy or chemoradiation followed by delayed surgery in locally advanced rectal cancer.
    Hoendervangers S; Couwenberg AM; Intven MPW; van Grevenstein WMU; Verkooijen HM
    Eur J Surg Oncol; 2018 Jul; 44(7):1013-1017. PubMed ID: 29650419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
    Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
    BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensified Total Neoadjuvant Therapy
    DE Felice F; Musio D; Iafrate F; Caponnetto S; Picone V; D'Ambrosio G; Magliocca FM; Tozzi F; DE Toma G; Tombolini V; Cortesi E
    Anticancer Res; 2022 Feb; 42(2):991-1000. PubMed ID: 35093899
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stepwise neoadjuvant chemoradiotherapy in the management of mid-low locally advanced rectal cancer.
    Zhang YX; Liu HY; Jiang B; Wang WY; Wang HB; Lu YJ
    Eur J Surg Oncol; 2020 Mar; 46(3):410-414. PubMed ID: 31627933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling.
    Liu H; Zhang Z; Zhen P; Zhou M
    J Immunol Res; 2021; 2021():6657012. PubMed ID: 33506057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a prediction model based on MRI for pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Wan L; Zhang C; Zhao Q; Meng Y; Zou S; Yang Y; Liu Y; Jiang J; Ye F; Ouyang H; Zhao X; Zhang H
    Abdom Radiol (NY); 2019 Sep; 44(9):2978-2987. PubMed ID: 31327039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting pathological complete response by comparing MRI-based radiomics pre- and postneoadjuvant radiotherapy for locally advanced rectal cancer.
    Li Y; Liu W; Pei Q; Zhao L; Güngör C; Zhu H; Song X; Li C; Zhou Z; Xu Y; Wang D; Tan F; Yang P; Pei H
    Cancer Med; 2019 Dec; 8(17):7244-7252. PubMed ID: 31642204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive value of (18)FDG PET-CT for tumour response in patients with locally advanced rectal cancer treated by preoperative chemoradiotherapy.
    Kim JW; Kim HC; Park JW; Park SC; Sohn DK; Choi HS; Kim DY; Chang HJ; Baek JY; Kim SY; Kim SK; Oh JH
    Int J Colorectal Dis; 2013 Sep; 28(9):1217-24. PubMed ID: 23404344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total neoadjuvant approach with FOLFOXIRI plus bevacizumab followed by chemoradiotherapy plus bevacizumab in locally advanced rectal cancer: the TRUST trial.
    Masi G; Vivaldi C; Fornaro L; Lonardi S; Buccianti P; Sainato A; Marcucci L; Martignetti A; Luca Urso ED; Castagna M; Fontanini G; Bergamo F; Musettini G; Urbani L; Sensi E; Balestri R; Montrone S; Pasqualetti F; Cremolini C; Di Paolo A; Zagonel V; Falcone A
    Eur J Cancer; 2019 Mar; 110():32-41. PubMed ID: 30739838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Worse treatment response to neoadjuvant chemoradiotherapy in young patients with locally advanced rectal cancer.
    Zhang Y; Yan L; Wu Y; Xu M; Liu X; Guan G
    BMC Cancer; 2020 Sep; 20(1):854. PubMed ID: 32891131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer.
    Seo I; Lee HW; Byun SJ; Park JY; Min H; Lee SH; Lee JS; Kim S; Bae SU
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33692216
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.